title: [Topics from "Overseas Drug Safety Information" in the past five years].
abstract: The Drug Safety Information Section of the Division of Safety Information on Drug, Food and Chemicals has been providing bulletins titled "Overseas Drug Safety Information" in Japanese since 2003. These bulletins comprise summarized and translated reports of important post-marketing drug safety information that are published by foreign regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medical Agency. A new issue of the bulletin is posted every two weeks on the website of the National Institute of Health Sciences, Japan; to date (May 2013), a total of 280 issues have been posted, covering approximately 2400 foreign news items and articles since its inception. Recently, visits to the bulletin website have been increasing: the number of hits for each issue totaled 570,000 in fiscal 2012. Among the "Overseas Drug Safety Information" issued in the past five years, I briefly describe here several topics which interested me: erythropoietin-stimulating agents in chronic kidney disease and their cardiovascular risk; bisphosphonates and atypical femur fracture; effectiveness of oral liquid cough medicines containing codeine in children; bevacizumab for metastatic breast cancer; and congenital abnormality associated with the use of antiepileptic drugs by pregnant women. I also describe the potential safety signals identified by FDA using its Adverse Event Reporting System, and their importance in ensuring the safe use of drugs in the post-marketing phase.
authors: Division of Safety Information on Drug, Food and Chemicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. amanuma@nihs.go.jp
authors: Kimiko
authors: K
authors: Amanuma
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000927:Anticonvulsants / Q000009:adverse effects; D000996:Antitussive Agents / Q000009:adverse effects; D000068258:Bevacizumab; D050071:Bone Density Conservation Agents / Q000009:adverse effects; D003061:Codeine / Q000009:adverse effects; D004164:Diphosphonates / Q000009:adverse effects; D004346:Drug Information Services / Q000639:trends*; D004921:Erythropoietin / Q000009:adverse effects; D006801:Humans; D011358:Product Surveillance, Postmarketing; D013997:Time Factors; D014481:United States; D016885:United States Department of Agriculture
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000927:Anticonvulsants; D000996:Antitussive Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004921:Erythropoietin; D000068258:Bevacizumab; D003061:Codeine